Amy L. Burroughs - Jan 30, 2025 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role: Chief Executive Officer, Director
Signature: /s/ David Strauss, as Attorney-in-Fact for Amy L. Burroughs
Stock symbol: TERN
Transactions as of: Jan 30, 2025
Transactions value $: $2,606
Form type: 4
Date filed: 2/3/2025, 07:25 PM
Previous filing: Dec 9, 2024
Next filing: May 30, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TERN	Common Stock	Purchase	$2.61K	+510	+2.67%	$5.11	19.6K	Nov 30, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TERN	Stock Option (Right to Buy)	Award	$0	+1.08M		$0.00	1.08M	Jan 30, 2025	Common Stock	1.08M	$4.64	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes an additional 510 shares acquired by the reporting person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2024 that was not previously reported on the reporting person's Form 4 filed on December 9, 2024 due to an administrative error.
F2	25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.